Long‐term survival under maintenance gemcitabine chemotherapy for metastatic transitional cell carcinoma

Lehmann, Jan; Retz, Margitta; Siemer, Stefan; Schreier, Ulrich; Zwergel, U.; Stöckle, Michael

doi:10.1111/j.1442-2042.2006.01471.x

Cited by 5 publications

(5 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this regard, gemcitabine is the first-ever chemotherapeutic agent that has been demonstrated to be capable of long-term control of tumor growth in a preclinical animal model of high-grade meningioma. Since gemcitabine has been reported to have an excellent, low toxicity profile suitable for long-term administration [ 17 , 27 – 30 ], our results suggest gemcitabine may be highly promising and advantageous in the long-term management of high-grade meningioma. It needs to be emphasized here that the gemcitabine regimen used in our xenograft study (intraperitoneal gemcitabine 20 mg/kg, twice a week for 4 weeks, given at the time of tumor regrowth) was not optimized and was far less intense compared with those (intraperitoneal gemcitabine 100∼125 mg/kg, twice a week continuously) widely used to treat xenograft tumors in nude mice [ 31 , 32 ], apparently allowing for increased dosing in future experiments.…”

Section: Discussionmentioning

confidence: 79%

Antitumor activity of gemcitabine against high-grade meningiomain vitroandin vivo

et al. 2017

View full text Add to dashboard Cite

Currently, there is no established therapeutic option for high-grade meningioma recurring after surgery and radiotherapy, and few chemotherapeutic agents are in development for the treatment of high-grade meningioma. Here in this study, we screened a panel of chemotherapeutic agents for their possible antitumor activity in high-grade meningioma and discovered that high-grade meningioma cells show a preferential sensitivity to antimetabolites, in particular, to gemcitabine. In vitro, gemcitabine inhibited the growth of high-grade meningioma cells effectively by inducing S-phase arrest and apoptotic cell death. In vivo, systemic gemcitabine chemotherapy suppressed not only tumor initiation but also inhibited the growth and achieved a long-term control of established tumors in xenograft models of high-grade meningioma. Histological analysis indicated that systemic gemcitabine blocks cell cycle progression and promotes apoptotic cell death in tumor cells in vivo. Together, our data demonstrate that gemcitabine exerts potent antitumor activity against high-grade meningioma through cytostatic and cytotoxic mechanisms. We therefore propose gemcitabine is a promising chemotherapeutic agent that warrants further investigation as a treatment option for high-grade meningioma.

show abstract

Section: Discussionmentioning

confidence: 79%

Antitumor activity of gemcitabine against high-grade meningiomain vitroandin vivo

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Lehmanne et al . reported administering 41 cycles of GEM maintenance monotherapy over a 28‐month period . In the current study, a maximum of 49 doses were administered.…”

Section: Discussionmentioning

confidence: 99%

Maintenance monotherapy with gemcitabine after standard platinum‐based chemotherapy in patients with advanced urothelial cancer

et al. 2015

View full text Add to dashboard Cite

Objectives: To investigate the outcomes of gemcitabine maintenance monotherapy treatment for metastatic urothelial cancer. Methods: Gemcitabine maintenance monotherapy was used for metastatic urothelial cancer patients after standard platinum-based chemotherapy. A standard dose of 1000 mg/m 2 /month was given. If patients suffered adverse events or a noticeably compromised quality of life, treatment intervals were extended and doses lowered. Patients with metastatic urothelial cancer receiving only best supportive care after standard chemotherapy served as the retrospective control group. Results: A total of 33 patients were included in the study group as well as in the control group. Maintenance therapy was administered a median of nine times (range 2-49 times) with a median dose of 984.2 mg (range 500-1400 mg) per time. An adverse event of the Common Terminology Criteria of Adverse Events grade 3 or greater was observed in 10 (30.3%) patients, while nine patients (27.3%) experienced hematotoxicity. After standard chemotherapy pretreatment, disease-specific survival in the maintenance therapy group was an average of 15.0 months, significantly more favorable (P < 0.001) than that of the control group (4.0 months). On multivariate analysis, efficacy of prior chemotherapy (P = 0.018), visceral metastasis (P = 0.007) and gemcitabine maintenance therapy (P < 0.001) were statistically significant prognostic parameters of disease-specific survival. Conclusion: The present study findings suggest that gemcitabine maintenance monotherapy in metastatic urothelial cancer might not only be useful as a palliative treatment, but it could also have a certain level of therapeutic effectiveness.

show abstract

“…The maintenance treatment in our study, the median (range) of number of cycles was (1-12)cycles with median dose of cycle (1000-1800mg) while Muto et al (12) the median was (2-49 ) cycles with median dose of cycle (500-1795mg), Kus and Aktas (14) the Median 7 (3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14) cycles with median dose of cycle (500-1800mg) and Lehmann et al (15) reported administrating 41 cycles of GEM maintenance monotherapy with cumulative total dose of gemcitabine 88.500mg.…”

Section: Discussionmentioning

confidence: 46%

“…In Lehmann et al (15) , case report of a 74-yearold man with widespread metastatic lung and retroperitoneal transitional cell carcinoma. Having been diagnosed with pT3 G2-3 urothelial cancer of the renal pelvis in 1999, the patient underwent a right nephroureterectomy and subsequently underwent adjuvant chemotherapy consisting of three cycles of cisplatin and methotrexate, followed by palliative maintenance gemcitabine monotherapy, with dosing of 1200 mg/m2 body surface on days 1 and 8 of a 21-day cycle.…”

Section: Discussionmentioning

confidence: 99%

Assessment of Outcomes of Maintenance Gemcitabine after Standard Chemotherapy in Metastatic Bladder Transitional Cell Carcinoma Patients

El-Azony,

El Hagrasy,

Fayed

et al. 2023

The Egyptian Journal of Hospital Medicine

View full text Add to dashboard Cite

Background: Gemcitabine as a maintenance therapy is cell cycle-specific with activity in the S-phase; it is used successfully in managing metastatic bladder cancer. Objective: The aim of the current study was to evaluate outcomes of maintenance gemcitabine monotherapy in metastatic bladder cancer patients after standard platinum-based chemotherapy. Patients and methods: A total of 36 patients were included in a randomized controlled clinical trial at Zagazig University Hospitals' Clinical Oncology and Nuclear Medicine Department; 18 patients as a maintenance group (group A) and 18 patients as a control group (group B), who had metastatic cancer of bladder and gave response to 1 st line platinum-based chemotherapy. Results: The visceral metastasis was not statistically significant prognostic parameter (P=0.137). Our study the "6 and 12 months" Progression Free Survival (PFS) in maintenance group (Group A) was 77.8% and 66.7% respectively versus 42.9% and 0% in control group (Group B) with mean PFS 10.16 months for maintenance group (Group A) and 5.12 months in control group (Group B) which was highly statistically significant different (P-value <0.001). Also "12 and 15 months" Overall survival (OS) was 77.8% and 75.7% respectively in maintenance cases versus 33.3% for both in control group with mean OS (16.05) months among maintenance group and (11.22) months among control subjects which was statistically significant different (P-value 0.008). Conclusion: Gemcitabine as a maintenance treatment showed good results in delaying disease progression and increased overall survival rate among cases who had metastatic transitional cell carcinoma of the bladder received standard platinum-based chemotherapy.

show abstract

Long‐term survival under maintenance gemcitabine chemotherapy for metastatic transitional cell carcinoma

Cited by 5 publications

References 4 publications

Antitumor activity of gemcitabine against high-grade meningiomain vitroandin vivo

Antitumor activity of gemcitabine against high-grade meningiomain vitroandin vivo

Maintenance monotherapy with gemcitabine after standard platinum‐based chemotherapy in patients with advanced urothelial cancer

Assessment of Outcomes of Maintenance Gemcitabine after Standard Chemotherapy in Metastatic Bladder Transitional Cell Carcinoma Patients

Contact Info

Product

Resources

About